Compare iShares Gold Trust (IAU) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Gold Trust vs Sanofi SA — how do they compare? iShares Gold Trust trades at $78.87 (market cap $61.51B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while iShares Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Gold Trust for 49 Days and Sanofi SA for 94 Days on average.
| IAU | SNY | |
|---|---|---|
Market Cap | $61.51B | $95.18B |
Volume | 3,206,729 | 2,995,646 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $52.34 |
52-Week Low | $74.21 | $39.51 |
Typical Hold Time | 49 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAU stock trades at $77.66 with a modest 0.78% daily gain amid bearish technical signals. The stock faces significant selling pressure with moving averages indicating a strong downtrend while oscillators remain neutral. Recent news highlights gold's sensitivity to interest rate expectations and Treasury yield movements, with mixed sentiment from financial media regarding near-term prospects.
The outlook remains cautious with technical indicators favoring sellers, though oversold conditions could present tactical opportunities. Key risks include persistent rate hike expectations and dollar strength, while institutional positioning suggests defensive sentiment prevails in the current macroeconomic environment.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Gold Trust
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
